生产企业：Bristol-Myers Squibb
BMS-986158 is under investigation in clinical trial NCT02419417 (Study of BMS-986158 in Subjects With Select Advanced Cancers).
BMS-986158 is under investigation in clinical trial NCT02419417 (Study of BMS-986158 in Subjects With Select Advanced Cancers).
BMS-986158 is a selective bromodomain and extraterminal domain (BET) inhibitor. It has demonstrated potent inhibition of BRD4 and C-MYC expression, and was identified for investigation due to its potent preclinical cytotoxic effects against hematologic malignancies and solid tumors.
Under investigation in patients with selected advanced solid tumors (phase 1/2a, NCT02419417). Also under investigation in a phase 1b/2 study evaluating combination therapy with the Janus kinase inhibitors ruxolitinib or fedratinib in patients with myelofibrosis (NCT04817007).
